Back to Explorer

Product Labeling for Laparoscopic Power Morcellators: Guidance for Industry and Food and Drug Administration Staff

FinalCenter for Devices and Radiological Health12/30/2020

Description

This guidancecontains recommendations concerning the content and format for certain labeling information for laparoscopic power morcellators (LPMs). The recommendations in this guidance reflect the state of the science and available technology regarding use of LPMs and are being made in light of scientific information that suggests that the use of these devices contributes to the dissemination and upstaging of an occult uterine malignancy in women undergoing laparoscopic gynecologic surgery for presumed fibroids. FDA is also recommending that manufacturers incorporate into the labeling for these devices information providing greater specificity regarding the risk of use as it relates to age, information regarding the risk of spreading malignant and benign uterine tissue, and information regarding the use of LPM containment systems. These labeling recommendations are intended to enhance, but not replace, the physician-patient discussion of the benefits and risks of use of LPMs that uniquely pertain to individual patients. FDA believes this effort will promote the safe and effective use of LPMs when used for gynecologic surgeries.

Scope & Applicability

Product Classes

3
Hysteroscopic morcellators

Devices excluded from the scope of this guidance due to different principles of operation.

LPM containment systems

Systems intended to isolate and contain tissue that is considered benign during morcellation.

Laparoscopic Power Morcellators

Guidance concerns content and format for certain labeling information for laparoscopic power morcellators (LPMs).; The primary device class addressed in the guidance for gynecologic surgery.

Stakeholders

1
Manufacturer

Entity responsible for submitting NDINs

Regulatory Context

Attributes

2
Post-menopausal

A patient state that serves as a contraindication for LPM use with suspected fibroids.

Upstaging

Refers to an increase in the extent or severity of the disease due to tumor spread.

Identified Hazards

Hazards

2
Spread of occult uterine malignancy

The primary safety concern associated with the use of LPMs.

Iatrogenic Dissemination

Spread of unsuspected cancerous tissue beyond the uterus when LPMs are used.

Related CFR Sections (1)

See Also (1)

Product Labeling for Laparoscopic Power Morcellators: Guidance for Industry and Food and Drug Administration Staff | Guideline Explorer | BioRegHub